The MoonStone Study: A Research Study for Adults with Relapsing MS
This message is intended for residents of the United States.
Our research partners at Zenas BioPharma are looking for people diagnosed with Relapsing Multiple Sclerosis (RMS) to participate in the MoonStone study.
What is the purpose of the study?
The purpose of the study is to assess the safety and effectiveness of a new investigational drug in MS called obexelimab. Obexelimab works to reduce the activity of B cells, a type of immune cell that can contribute to MS.
What does the study involve?
Participation in the MoonStone study is up to 92 weeks (1.8 years), with regularly scheduled clinic visits. These onsite visits will typically include: physical exams, blood tests, neurological tests, and magnetic resonance imaging scans (MRIs), among other activities.
- After the 4-week screening period, participants will be randomly assigned to receive either obexelimab or a placebo weekly for 12 weeks, followed by all participants receiving obexelimab weekly for the remaining 64 weeks.
- After the treatment period, there is a 12-week follow-up period in which no treatment will be given.
You will receive either obexelimab or a placebo as a weekly injection under the skin (subcutaneous injection). For the first month, these injections will take place at the study clinic so the study team can monitor you closely. After that, you and your study doctor can decide if you’ll continue coming to the clinic for your injections or if you can start giving them at home.
Transportation and meals will be covered for all participants.
Who can participate? The study is enrolling people who:
- Are age 18 to 60
- Have a diagnosis of relapsing MS (relapsing-remitting MS or active secondary progressive MS)
- Have an EDSS of ≤ 5.5 at the Screening Visit
- Have had:
- At least 1 documented relapse within the previous year, or
- At least 2 documented relapses within the previous 2 years, or
- At least 1 active contrast-enhancing brain lesion on an MRI scan in the 6 months prior to screening
There are other eligibility criteria as well, which you can discuss further with your local site.
How can I learn more? To learn more about this study, please contact Zenas BioPharma at 833-269-4696 or at clinicaltrialsinfo@zenasbio.com. For a list of study sites, visit https://clinicaltrials.gov/study/NCT06564311. The clinical sites taking part are listed in the Contacts and Locations section.
Have you ever used a mobile app to manage your MS? Researchers would like to hear from you!
A research team at Kadir Has University in Turkey is conducting a study about mobile applications designed for MS management. Their goal of this research is to understand the value that these apps provide to people with MS so that future tools can be more relevant and effective. This is an international study taking place in Turkey, Germany, Serbia, Canada, the UK, Australia, and the USA.
The researchers have developed a short 10-minute survey for people with MS. If you have ever used an app to manage your MS, you are invited to take the survey:
For any questions about the study, please email Ece Yılmaz Kozlu at ece.kozlu@stu.khas.edu.tr.
Participants will be offered a $50 Amazon gift card for completing the interviews.
A new topic for the Our Questions Have Power program!
When it comes to MS symptoms and how to manage them, what questions are most important to you? What symptom-related topics do you wish researchers were studying? Your questions are valuable and we invite you to share them through the Our Questions Have Power program on the iConquerMS website.
The Our Questions Have Power program was launched in March 2021 with an initial focus on COVID-19. Questions submitted by iConquerMS members have helped shape the COVER-MS vaccination study and are being shared with the research community to guide other efforts.
We’re now extending Our Questions Have Power to include a second topic: MS symptoms and their management and treatment. As before, you’re invited to share questions on this topic that you think should be studied and to vote on questions submitted by other iConquerMS members. We’ll share these questions with people affected by MS, researchers, healthcare professionals, advocates, and funders – and, together, we’ll work to launch research studies to answer those questions.
It’s easy to share your ideas and input in Our Questions Have Power!
